Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 3,800.00
+70.00 (1.88%)
At close: Jul 27, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 161.33 billion as of July 28, 2026. Its market cap has increased by 82.75% in one year.
Market Cap
161.33B
Enterprise Value
141.33B
Revenue
24.02B
Ranking
n/a
PE Ratio
n/a
Stock Price
3,800.00
ChartMarket Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 161.33B, an increase of 124.46%. That is a compound annual growth rate of 11.24%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 28, 2026 | 161.33B | -32.32% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| S.Biomedics | 209.93B |
| Kangstem Biotech | 198.92B |
| curacle co.,ltd. | 191.31B |
| NIBEC | 161.76B |
| Ensol Biosciences | 161.33B |
| Kanaph Therapeutics | 160.52B |
| Bio Solution | 158.70B |
| ISU Abxis | 150.26B |